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Membrane-associated progesterone receptors (MAPR) are a group of four rather
small, partially homologous proteins, which share a similar non-covalent heme-binding
domain that is related to cytochrome b5, a well-known functional interaction partner
of microsomal cytochrome P450 (CYP) monooxygenase systems. Apart from their
structural similarities the four proteins progesterone membrane component 1 (PGRMC1,
also referred to as IZA, sigma-2 receptor, Dap1), PGRMC2, neudesin (NENF) and
neuferricin (CYB5D2) display surprisingly divergent and multifunctional physiological
properties related to cholesterol/steroid biosynthesis, drug metabolism and response,
iron homeostasis, heme trafficking, energy metabolism, autophagy, apoptosis, cell cycle
regulation, cell migration, neural functions, and tumorigenesis and cancer progression.
The purpose of this mini-review is to briefly summarize the structural and functional
properties of MAPRs with particular focus on their interactions with the CYP system.
For PGRMC1, originally identified as a non-canonical progesterone-binding protein that
mediates some immediate non-genomic actions of progesterone, available evidence
indicates mainly activating interactions with steroidogenic CYPs including CYP11A1,
CYP21A2, CYP17, CYP19, CYP51A1, and CYP61A1, while interactions with drug
metabolizing CYPs including CYP2C2, CYP2C8, CYP2C9, CYP2E1, and CYP3A4 were
either ineffective or slightly inhibitory. For the other MAPRs the evidence is so far less
conclusive. We also point out that experimental limitations question some of the previous
conclusions. Use of appropriate model systems should help to further clarify the true
impact of these proteins on CYP-mediated metabolic pathways.
Keywords: cytochrome P450, membrane-associated progesterone receptor, neudesin, neuferricin, PGRMC1,
PGRMC2, protein-protein interaction
INTRODUCTION
Inter- and intraindividual variability in the expression and activity of drug metabolizing enzymes,
transporters and their regulators is a major determinant of drug response, both in terms of
drug efficacy and adverse events. The cytochrome P450 enzymes, a superfamily of microsomal
and mitochondrial hemoproteins (CYP), are particularly variable between and within subjects
(Zanger and Schwab, 2013). Despite half a century of pharmacogenetic research, much of the
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interindividual variation remains unexplained (Meyer, 2004;
Lauschke and Ingelman-Sundberg, 2015). This “dark variation”
may be explained by so far unidentified or unexplored genes
that influence drug metabolism at the level of protein-protein
interactions (PPI). The multiple monooxygenase functions
of microsomal CYP enzymes strictly depend on PPI with
the single microsomal flavoprotein NADPH:cytochrome P450
oxidoreductase (POR) to allow electron transfer from NADPH
to the heme iron (Pandey and Fluck, 2013; Kandel and Lampe,
2014). Since POR is present in the endoplasmic reticulum (ER)
at sub-stoichiometric amounts compared to CYP, it has been
proposed that their interactions involve transient oligomeric
complexes (Backes and Kelley, 2003). In contrast to POR, the
small hemoprotein cytochrome b5 (CYB5), which is located
together with CYB5-reductase and the other components on
the cytoplasmic side of the ER, is not an obligatory electron
donor for CYPs but acts as modulator of enzyme activity
in CYP- and sometimes substrate-dependent way (Henderson
et al., 2015). For a long time, POR and CYB5 were the only
proteins known to functionally interact with CYPs during the
microsomal monooxygenase reaction. Only in recent years new
PPI candidates for cytochromes P450 have been considered (see
other articles in this Research Topic).
A particularly intriguing group of proteins are the so-
called “membrane-associated progesterone receptor” (MAPR)
proteins. The term emphasizes their common ability to bind
progesterone and to elicit rapid steroidal effects independent of
the classical steroid hormone receptors (Wehling, 1997; Mifsud
and Bateman, 2002). Following the initial purification of a high-
affinity progesterone-binding protein (later termed progesterone
receptor membrane component 1, PGRMC1) from porcine liver
membranes and cDNA cloning (Meyer et al., 1996; Gerdes
et al., 1998), MAPRs were recognized as evolutionarily conserved,
distant homologs of CYB5, that can principally interact with
CYPs and modulate their functions (Min et al., 2004; Hughes
et al., 2007).
The purpose of this review is to provide an overview
and critical assessment of the studies elucidating potential
interactions of MAPRs with CYPs. Apart from this, MAPRs
interact with an increasing number of different proteins and
are involved in a wide variety of cellular functions including
cholesterol and steroid homeostasis, cell cycle regulation, cell
migration, neurogenesis, autophagy, heme homeostasis and more
that are only briefly mentioned but not the focus of this review.
Readers interested in these aspects are referred to excellent
reviews by others (Losel et al., 2008; Ahmed et al., 2012; Kimura
et al., 2012; Neubauer et al., 2013; Cahill et al., 2016; Hasegawa
et al., 2016).
MOLECULAR, BIOCHEMICAL AND
CELLULAR PROPERTIES OF MAPRs
The four MAPR proteins PGRMC1, PGRMC2, neuferricin
and neudesin share a homologous CYB5-like heme/steroid-
binding domain but lack homology with the classical nuclear or
membrane-bound steroid receptors (Mifsud and Bateman, 2002;
Min et al., 2005; Kimura et al., 2012). Recent crystallographic
analyses confirmed the hemoprotein nature of PGRMC1 with
a special five-coordinated heme iron involving Tyr113, as
opposed to the six-coordinated heme with two axial histidines
in CYB5 (Min et al., 2005; Kaluka et al., 2015; Kabe et al.,
2016). Interestingly, this difference allows human PGRMC1
to form stable homodimers through hydrophobic heme-heme
stacking interactions, explaining earlier observations of dimeric
complexes (Min et al., 2004; Kabe et al., 2016). Since the heme-
binding residues are conserved among MAPRs, these proteins
may all share the ability of heme-dependent homo- and/or
heterodimerization (Peluso et al., 2014). Although PGRMC1 had
originally been defined as a component of a progesterone-binding
protein complex with affinities in the nM range (Meyer et al.,
1996), it remained questionable whether progesterone actually
binds directly to PGRMC1 itself. A recent study provided first
qualitative spectroscopic evidence that this is indeed the case,
while it is still not proven for other MAPRs (Kaluka et al., 2015).
PRGMC1
PRGMC1 is predominantly expressed in mammalian liver
and kidney but also found in steroidogenic and reproductive
tissues, brain, breast, heart, lung, skeletal muscle, pancreas,
and other organs (Gerdes et al., 1998; Kimura et al., 2012).
Typically it is colocalized with CYPs in the smooth ER, but
it has also been localized in the nucleus, cytoplasm, plasma
membrane, and mitochondria (Kimura et al., 2012; Piel et al.,
2016). Expression is inducible by carcinogens, including dioxin
(Selmin et al., 1996), and increased in breast and other tumors,
where it contributes to cancer progression (Neubauer et al.,
2008; Ruan et al., 2017). Reported physiological functions
affected by PGRMC1 include cholesterol/steroid biosynthesis and
metabolism (see below), iron homeostasis and heme trafficking
by regulating hepcidin expression and ferrochelatase activity
(Craven et al., 2007; Li et al., 2016; Piel et al., 2016), promotion
of autophagy through interaction with MAP1LC3B (Mir et al.,
2013), regulation of cell cycle, proliferation, and cell death (Peluso
et al., 2014), maintenance of female reproductive functions in
PGRMC1 conditional knock-out mice (McCallum et al., 2016),
cell migration and invasion (Sueldo et al., 2015), amyloid beta
binding and synaptotoxicity in a mouse model of Alzheimer’s
disease (Izzo et al., 2014), and others (Losel et al., 2008; Ahmed
et al., 2012; Neubauer et al., 2013; Cahill et al., 2016; Hasegawa
et al., 2016). A growing number of studies supports furthermore
a role of PGRMC1 in drug response and as potential drug target,
e.g., by increasing susceptibility to tyrosine kinase inhibitors
(Ahmed et al., 2010), decreasing doxorubicin cytotoxicity (Lin
et al., 2015), or mediating atypical antipsychotic drug-induced
lipid disturbances (Cai et al., 2015). Importantly, in 2011
PGRMC1 was identified as the elusive sigma 2 receptor (S2R), an
intracellular orphan receptor that binds to many drugs and that is
abundant in liver and kidney (Xu et al., 2011; Ahmed et al., 2012).
PGRMC2
PGRMC2 harbors a structurally similar CYB5 domain as
PGRMC1, while there are differences in the N-terminal
transmembrane domain (Cahill, 2007). Human PGRMC2
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protein is 247 amino acids in length. Despite its structural
similarities to PGRMC1, PGRMC2 has been less well studied
(Wendler and Wehling, 2013; Hasegawa et al., 2016). Expression
appears to be ubiquitous with similar intracellular localization
(Chen et al., 2010; Intlekofer and Petersen, 2011). In SKOV-3
ovarian cancer cells no differences between PGRMC1 and 2 in
regard to cell viability or response to cisplatin and progesterone
were found, but only PGRMC2 inhibited cell migration (Albrecht
et al., 2012). PGRMC2 was also implicated in cell cycle regulation
(Peluso et al., 2014).
Neudesin
Neudesin was originally identified as a mouse secreted protein
with neurotrophic activity and termed neuron-derived
neurotrophic factor (NENF) (Kimura et al., 2005). In adult
mice, neudesin was expressed preferentially in the CNS spinal
cord but also in several peripheral tissues (Kimura et al., 2005,
2012). NMR studies suggested a similar structure with a potential
heme-binding pocket (Han et al., 2012). The physiological roles
of neudesin as a secreted protein appear to be significantly
different from PGRMC1/2, including particularly neurotrophic
activity that required heme binding and was mediated through
mitogen-activated protein (MAP) and phosphatidylinositol
3-kinase (PI-3K) pathways (Kimura et al., 2005). Several
neurological functions have been studied in knockout mice as
summarized elsewhere (Ohta et al., 2015). Extracellular/secreted
neudesin may be involved in carcinogen resistance and tumor cell
immortalization, although specific receptors remain unknown
(Ohta et al., 2015).
Neuferricin
Neuferricin (CYP5D2) was discovered via a homology-
based search of the CYB5-like heme/steroid-binding domain
of neudesin, alternatively termed cytochrome B5 Domain
Containing 2 (CYB5D2) (Kimura et al., 2010). Neuferricin is
also widely expressed in several tissues including the CNS,
heart, adrenal glands, and kidneys. Human neuferricin is 264
amino acids in length and includes a cleavable signal sequence
at its N terminus followed by a heme-binding domain that
may involve aspartic acid (D86) instead of tyrosine in heme
binding (Bruce and Rybak, 2014). CYB5D2 can be detected as
secreted hemoprotein in some cell lines but also colocalized
with POR in the ER (Xie et al., 2011; Bruce and Rybak, 2014).
Ectopic CYB5D2 expression inhibited cell proliferation and
anchorage-independent colony growth of HeLa cells (Bruce and
Rybak, 2014).
SPECIFIC INVOLVEMENT OF MAPRS IN
CYP FUNCTIONS
The available evidence suggesting that MAPR proteins can
interact with the microsomal CYP-monooxygenase system to
modulate its function is based on different species from
yeast to human, various experimental systems, and relates to
CYP enzymes catalyzing steroidogenic or xenobiotic reactions
(Table 1). The levels of interactions may include not only physical
PPIs but also indirect influences via heme transfer, heme and iron
homeostasis, and transcriptional regulation (Figure 1).
PGRMC1
First indications for a link between PGRMC1 and CYP function
came from two independent studies. Identification of the
adrenal “inner zone antigen” (IZA) as a MAPR member (Raza
et al., 2001), its localization in both steroidogenic and steroid
metabolizing tissues and the fact that an anti-IZA monoclonal
antibody decreased certain adrenal steroidhydroxylase activities
led the authors to suggest a function in steroid hormone
biosynthesis and/or metabolism (Min et al., 2004). By
coexpressing IZA/PGRMC1 with CYP21A2, CYP11B1 or
CYP17 in COS-7 cells they found differential effects, namely
enhancement of progesterone 21-hydroxylation, no effect on
progesterone 11β- or 17α-hydroxylation, and activation of
the CYP17-catalyzed 17–20 lyase reaction (Min et al., 2004,
2005). About at the same time a search for novel yeast genes
involved in DNA damage response led to the identification of
Dap1 (Hand et al., 2003). Steroid analyses of Saccharomyces
cerevisiae yeast cells lacking Dap1 revealed decreased levels of
ergosterol but increased levels of its intermediates, suggesting a
partial defect in sterol synthesis by lanosterol-14-demethylase,
the highly conserved yeast-essential Erg11/CYP51 (Hand et al.,
2003). Genetic follow-up studies supported a model in which
heme binding by Dap1 is required to activate Erg11/CYP51,
although a Dap1-Erg11 complex could not be directly detected
by immunoprecipitation experiments (Mallory et al., 2005).
Further evidence for a role of Dap1/PGRMC1 in CYP
function was provided by Hughes et al. (2007) working with
Schizosaccharomyces pombe. After confirming that fission yeast
Dap1 is also a hemoprotein and directly binds to and activates
enzymatic activities of CYP51A1 (Erg11) and CYP61A1 (Erg5),
they investigated whether PGRMC1 is required for cholesterol
synthesis in mammals (Hughes et al., 2007). RNA interference-
mediated knock-down of hPGRMC1 in HEK293 cells resulted in
lanosterol accumulation, indicating that PGRMC1 was required
for the demethylation of lanosterol by the Erg11 homolog,
CYP51A1. Using a coexpression/coimmunoprecipitation
approach PGRMC1 was shown to form a stable complex
with CYP51A1 (Hughes et al., 2007). The authors applied the
latter experiment also to CYP7A1, CYP21A2, and CYP3A4,
demonstrating physically stable PGRMC1-CYP complexes in
all cases. PGRMC1 was later shown to also activate CYP19
aromatase (Ahmed et al., 2012). Collectively these studies
strongly suggest the ability of PGRMC1 to form functional
PPIs with steroidogenic and possibly other CYPs. Interestingly,
the documented functional influence of PGRMC1 on various
steroidogenic CYPs appeared to be generally positive.
The above mentioned ability of PGRMC1 to complex with
CYP3A4 first indicated the possibility that PGRMC1 may also
interact with drug metabolizing P450s (Hughes et al., 2007).
Although the authors emphasized the apparent existence of
stoichiometric and physically stable complexes, it should be
kept in mind that the experimental conditions of overexpressing
tagged and manipulated proteins were quite artificial and that it
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TABLE 1 | Functional interactions between membrane-associated progesterone receptors (MAPR) proteins and cytochrome P450 system.
MAPR CYP System Enzymatic activity Direction of influence Reference
IZA/PGRMC1 (rat) CYP21A2 (rat) Inhibition by anti-IZA
monoclonal antibody
Progesterone 21-hydroxylase Activation Laird et al., 1988
IZA/PGRMC1 (rat) CYP21A2 (rat) COS-7 cell coexpression Progesterone 21-hydroxylase Activation Min et al., 2004
IZA/PGRMC1 (rat) CYP17 (guinea pig) COS-7 cell coexpression Progesterone 17α-hydroxylase Little or no influence Min et al., 2005
IZA/PGRMC1 (rat) CYP17 (guinea pig) COS-7 cell coexpression 17α-Hydroxyprogesterone
17–20 lyase
Activation Min et al., 2005
IZA/PGRMC1 (rat) CYP11B1 (rat) COS-7 cell coexpression Progesterone 11β-hydroxylase Little or no influence Min et al., 2004
PGRMC1 (human) CYP19A1 (human) CYP19-engineered MCF-7
human breast cancer cells
RNAi knockdown
Androst-4-ene-3,17-dione
conversion
Activation Ahmed et al., 2012
Dap1/PGRMC1
(S. cerevisiae)
CYP51A1 (S. cerevisiae) S. cerevisiae genetics Lanosterol-14-demethylase Activation Hand et al., 2003
Mallory et al., 2005
Dap1/PGRMC1
(S. pombe)
CYP51A1 (S. pombe) S. pombe strain lacking
DAP1
Lanosterol-14-demethylase Activation Hughes et al., 2007
Dap1/PGRMC1
(S. pombe)
CYP61A1 (S. pombe) S. pombe strain lacking
DAP1
Lanosterol-22-desaturase Activation Hughes et al., 2007
PGRMC1 (rabbit) CYP2C2 (rabbit) HEK293, HepG2 cell
coexpression
Luciferin 6′ methyl ether
O-demethylation
Inhibition Szczesna-Skorupa
and Kemper, 2011
PGRMC1 (human) CYP2C8 (human) HEK293, HepG2 cell
coexpression
Luciferin 6′ methyl ether
O-demethylation
Inhibition Szczesna-Skorupa
and Kemper, 2011
PGRMC1 (human) CYP3A4 (human) HEK293, HepG2 cell
coexpression
Luciferin 6′ pentafluorobenzyl
ether depentafluorobenzylation
Inhibition Szczesna-Skorupa
and Kemper, 2011
PGRMC1 (human) CYP2C9 (human) HepG2 coexpression,
human hepatocytes RNAi
knockdown
S-Warfarin 7-hydroxylase and
diclofenac 4′-hydroxylase
Inhibition Oda et al., 2011
PGRMC1 (human) CYP3A4 (human) HepG2 coexpression,
human hepatocytes RNAi
knockdown
Testosterone 6β-hydroxylase
and midazolam 1′-hydroxylase
Inhibition Oda et al., 2011
PGRMC1 (human) CYP2E1 (human) HepG2 coexpression,
human hepatocytes RNAi
knockdown
Chlorzoxazone 6-hydroxylase
and 7-ethoxycoumarin
O-deethylase
No influence Oda et al., 2011
PGRMC2 (human) CYP3A4 (human) Human liver genetic
association
Atorvastatin 2-hydroxylase Inhibition Klein et al., 2012
CYB5D2 (human) CYP3A4 (human) Hela cell expression and
RNAi knockdown
Luciferin 6′ pentafluorobenzyl
ether depentafluorobenzylation
Activation Bruce and Rybak,
2014
is unknown, whether PGRMC1 abundance in the ER is sufficient
for the formation of 1:1 complexes at higher concentrations.
Two studies have investigated the question whether PGRMC1
affects drug metabolizing CYPs functionally. Szczesna-Skorupa
and Kemper, using cotransfection and coimmunoprecipitation
of FLAG-tagged PGRMC1 with variously tagged rabbit CYP2C2
and human CYP2C8 and CYP3A4 in HEK293 cells could show
efficient binding of PGRMC1 to all three CYPs, for CYP2C2
mainly mediated by the cytoplasmic domain (Szczesna-Skorupa
and Kemper, 2011). The effect of PGRMC1 on enzymatic activity
was tested by siRNA-mediated downregulation of endogenous
PGRMC1, and by coexpression with functional CYP plasmids
in HEK293 and HepG2 hepatoma cells (Table 1). Surprisingly,
the results were quite opposite to those of steroidogenic
CYPs, as CYP activities were either unchanged or slightly
increased in PGRMC1-deficient cells, but decreased in presence
of exogenously expressed PGRMC1. Interestingly, the inhibitory
effect could be partially and CYP isoform-dependently reversed
by increased expression of POR, also shown to directly
interact with PGRMC1. The authors concluded that in contrast
to steroidogenic CYPs, PGRMC1 is not required by drug
metabolizing CYPs for enzymatic activity and that the CYP
differential effects may be explained by the intricate PPI affinities
in triple CYP-POR-PGRMC1 systems (Szczesna-Skorupa and
Kemper, 2011).
Oda et al. (2011) found differential effects of PGRMC1
cotransfection with CYP2C9, CYP2E1, and CYP3A4 in HepG2
cells. While CYP3A4 had increased Km and decreased Vmax with
two different substrates (testosterone and midazolam), CYP2C9
Km was unchanged but Vmax also decreased, and CYP2E1 activity
(chlorzoxazone, 7-ethoxycoumarin) remained unchanged. The
authors also confirmed direct interactions of PGRMC1 with all
three CYPs (Oda et al., 2011).
More recently, Kabe et al. (2016) in their structural study
investigated the relevance of heme-mediated dimerization on
functional interactions with human CYPs. By incubation of
FLAG-tagged PGRMC1 with microsomes from insect-cells
expressing POR, CYB5, and either CYP1A2 or CYP3A4, they
showed by immunoprecipitation that only wild-type PGRMC1
but not the Y113F mutant interacted with the present CYP.
The interaction with CYP1A2 was furthermore blocked by
incubation with a CO-generating reagent, indicating that
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FIGURE 1 | Confirmed and hypothetical interactions of membrane-associated progesterone receptors (MAPRs) with microsomal cytochrome P450
(CYP) system. MAPR proteins located in the endoplasmic reticulum (ER) membrane can directly interact with each other to form homo- and heterodimers; MAPR
monomers and dimers may participate in PPIs with P450 oxidoreductase (POR), cytochrome b5 (CYB5) and/or CYPs. Transfer of heme to CYB5 and possibly CYPs
as well as involvement in iron/heme homeostasis may influence heme integration and thus CYP function. Furthermore, MAPRs participate in diverse signaling
pathways that may affect transcriptional regulation of CYP gene expression (double arrows, confirmed protein-protein interactions; solid arrows, confirmed influence;
dashed arrows, hypothetical influence).
PGRMC1 dimerization is necessary for the interaction. To test
whether CYP-mediated enzymatic functions are affected they
used HCT116 human colon cancer cells stably expressing control
or PGRMC1 shRNA to reduce endogenous PGRMC1 expression
and incubated them with doxorubicin. PGRMC1 knock-down
suppressed the conversion of doxorubicin to doxorubicinol,
and increased cell sensitivity to doxorubicinol. This effect was
partially reversed by coexpression of the wild-type PGRMC1
but not of the Y113F mutant. Assuming that CYP2D6 and
CYP3A4 are the relevant enzymes for doxorubicinol-formation
in HCT116 cells, the authors concluded that interaction of
CYPs with the PGRMC1 dimer was a crucial component of
CYP activity (Kabe et al., 2016). However, this conclusion is
severely flawed because the metabolic step from doxorubicin to
doxorubicinol is not a hydroxylation but in fact a 2-electron
reduction of a ketogroup to an aliphatic alcohol. This reduction is
not catalyzed by CYPs 2D6 and 3A4 as indicated in the paper, but
mainly by cytosolic carbonyl reductase 1 (Kassner et al., 2008).
Furthermore the use of HCT116 cells with very low CYP3A4
expression seems inappropriate for CYP metabolism studies
(Habano et al., 2011). We therefore believe that this and other
previously reported functional and cellular effects of PGRMC1
on doxorubicin-metabolism or cytotoxicity (e.g., Friel et al., 2015;
Lin et al., 2015) are not due to interactions with CYPs but must
have other reasons.
Finally the recent study by Piel et al. (2016) should be
mentioned here again as it demonstrated a role of PGRMC1 in
heme homeostasis and its ability to directly transfer heme to
CYB5 in vitro. The authors suggest that PGRMC1 may be a heme
chaperone or sensor, and this could of course have additional
direct or indirect implications for CYP function (Figure 1).
PGRMC2
Despite its high similarity to PGRMC1 much less is known
about PGRMC2 (Wendler and Wehling, 2013). The first
observation indicating a role in CYP function was made in
a pharmacogenetic screen in human livers, where an intronic
PGRMC2 polymorphism (rs3733260) was significantly associated
with lower levels of mRNA expression, protein and enzyme
activity (Klein et al., 2012). Although the directionality of this
influence was the same as that observed for PGRMC1 and
CYP3A4, it should be noted that the data are correlative in nature
and would also be compatible with gene regulatory mechanisms
(Figure 1). Stable physical interactions of PGRMC2 were
demonstrated in human embryonic kidney cells for CYP1A2 and
CYP3A4, suggesting similar interaction potential as for PGRMC1
(Albrecht et al., 2012). It should thus be interesting to investigate
the potential of PGRMC2 to modulate CYP function and/or
expression in a valid system.
Neudesin and Neuferricin
To our knowledge, only one study (Bruce and Rybak, 2014)
directly addressed the potential interaction of these proteins
with CYPs. The authors showed that neuferricin is colocalized
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with POR in HeLa cells. Neuferricin knockdown reduced
endogenous CYP51A1 (lanosterol demethylase) protein levels,
which lead to increased sensitivity toward mevalonate, an
intermediate of the cholesterol synthesis pathway. This suggested
a stabilizing role of neuferricin for CYP51A1, as previously
described for PGRMC1 and Dap1 (Hughes et al., 2007). Data
further indicated that neuferricin knockdown also decreased
the fraction of endogenous CYP3A4 activity that was enhanced
by overexpressed POR, indicating activation of CYP3A4 by
neuferricin, in contrast to the inhibitory effects of PGRMC1 (see
above). However, it should be pointed out that the neuferricin
data consists of a single point measurement carried out in a cell
model that is not usually applied for drug metabolism studies,
leaving it unclear whether the conclusion can be generalized.
The same argument applies to the studies on HeLa cell exposure
to chemotherapeutic agents such as paclitaxel, cisplatin, and
doxorubicin, which resulted in increased sensitivities in CYB5D2
deficient cells (Bruce and Rybak, 2014). Since the expression
levels of drug metabolizing CYPs are very low in HeLa cells,
the construction of a link between CYB5D2 and function of
drug metabolizing CYPs based on these data is in our opinion
questionable.
CONCLUSION AND FUTURE
PERSPECTIVES
Direct physical interactions of MAPRs, especially of mammalian
PGRMC1 or yeast Dap1, with various cytochromes P450 are
strongly supported by experimental data. However, data are still
limited and in our view use of inappropriate model systems
questions some conclusions on functional interactions with
CYPs. Open questions that remain to be studied are, for example:
which direct MAPR-CYP interactions are possible in binary,
ternary, and higher order complexes and how do they affect
function; how could MAPRs indirectly influence CYP function,
e.g., by regulating heme supply and protein stability; are there
MAPR signaling pathways that affect transcriptional regulation
of CYPs and possibly other drug metabolizing enzymes, etc. It
is of eminent importance that valid experimental systems, which
express the CYP system at physiological levels, e.g., primary
hepatocytes or genetically modified mice, are used in future
studies.
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